| ²é¿´: 1078 | »Ø¸´: 5 | ||
yunfeng5609Ìú³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
Çó1¾ä»°·Òë
|
| Ñо¿²ÝÎÚ¼×ËØµÄCYP´úлÇé¿ö£¬¶ÔÓÚÅжÏÁÙ´²ÅäÎéʹÓòÝÎÚ¼×ËØÊ±¿ÉÄÜ·¢ÉúµÄÒ©Îï¼äÏ໥×÷Óã¬Ìá¸ßÁÙ´²Ê¹ÓòÝÎÚ¼×ËØµÄ°²È«ÐÔÓÐÖØÒªÒâÒå¡£ |
» ²ÂÄãϲ»¶
285Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÉúÎïѧÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0854Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
319·Ö085702°²È«¹¤³ÌÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©
ÒѾÓÐ6È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ14È˻ظ´
0703»¯Ñ§µ÷¼Á325·Ö
ÒѾÓÐ12È˻ظ´
ÇóÖú071001µ÷¼Á£¡£¡£¡
ÒѾÓÐ5È˻ظ´
¹¤¿Æ370Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ10È˻ظ´
xmcer
Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)
- ·ÒëEPI: 2
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 7638.4
- ºì»¨: 2
- ɳ·¢: 7
- Ìû×Ó: 5442
- ÔÚÏß: 224Сʱ
- ³æºÅ: 1215434
- ×¢²á: 2011-02-27
- רҵ: ¼ÆËã»úÓ¦Óü¼Êõ
2Â¥2014-02-12 19:42:55
dailun20
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 2
- Ó¦Öú: 22 (СѧÉú)
- ¹ó±ö: 0.001
- ½ð±Ò: 2337.4
- É¢½ð: 5553
- ºì»¨: 5
- Ìû×Ó: 657
- ÔÚÏß: 357.9Сʱ
- ³æºÅ: 1353845
- ×¢²á: 2011-07-23
- ÐÔ±ð: GG
- רҵ: ±íÃæ¡¢ÐÎ̬ÓëÐÎò·ÖÎö
3Â¥2014-02-14 11:56:01
RXMCDM
°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 530
- Ó¦Öú: 401 (˶ʿ)
- ¹ó±ö: 1.908
- ½ð±Ò: 38947.6
- É¢½ð: 4908
- ºì»¨: 88
- ɳ·¢: 4
- Ìû×Ó: 11453
- ÔÚÏß: 1355.6Сʱ
- ³æºÅ: 2739168
- ×¢²á: 2013-10-20
- ÐÔ±ð: GG
- רҵ: Ò»°ã¹ÜÀíÀíÂÛÓëÑо¿·½·¨ÂÛ
- ¹ÜϽ: ÂÛÎÄ·Òë

4Â¥2014-02-14 12:50:33
ÓÀÔ¶µÄNO.1
½û³æ (ÎÄ̳¾«Ó¢)
RXMCDM: ¶àлӦÖú£¡ 2014-02-25 20:37:20
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
5Â¥2014-02-23 16:34:53
ÄãÎÒ¹²Ãã
½ð³æ (СÓÐÃûÆø)
- ·ÒëEPI: 4
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 632.7
- É¢½ð: 40
- ºì»¨: 1
- Ìû×Ó: 243
- ÔÚÏß: 83.6Сʱ
- ³æºÅ: 1650747
- ×¢²á: 2012-02-28
- ÐÔ±ð: MM
- רҵ: ÌìȻҩÎﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-03-05 16:55:55
yunfeng5609(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-03-15 23:02:31
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-03-05 16:55:55
yunfeng5609(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-03-15 23:02:31
| To study the CYP metabolic of bulleyaconitine A,which has an important significance for determine the possible interactions between drugs when clinical compatibility using bulleyaconitine A ,and help to improve the safety of clinical use bulleyaconitine A |

6Â¥2014-03-05 15:58:51














»Ø¸´´ËÂ¥

